- Previous Close
0.00 - Open
0.00 - Bid --
- Ask --
- Day's Range
0.00 - 0.00 - 52 Week Range
0.00 - 64,000.00 - Volume
0 - Avg. Volume
1,113,089 - Market Cap (intraday)
720.558B - Beta (5Y Monthly) 0.75
- PE Ratio (TTM)
-- - EPS (TTM)
-- - Earnings Date May 12, 2025 - May 16, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
OliX Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on developing RNA interference (RNAi) therapeutics for dermal, ophthalmic, and pulmonary diseases. The company's products pipeline includes OLX101A for skin scar; OLX104C for androgenic alopecia; OLX301A for age-related macular degeneration; OLX702A for metabolic dysfunction-associated steatohepatitis; OLX703A for hepatitis; and OLX301D for subretinal fibrosis. The company has a license and collaboration agreement with Hansoh Pharmaceuticals; development collaboration with Korea Institute of Technology; and research collaboration with the University of Virginia. The company was formerly known as Biomolecular Therapeutics Inc. OliX Pharmaceuticals, Inc. was founded in 2010 and is headquartered in Suwon-si, South Korea.
www.olixpharma.comRecent News: 226950.KQ
View MorePerformance Overview: 226950.KQ
Trailing total returns as of 4/3/2025, which may include dividends or other distributions. Benchmark is KOSPI Composite Index (^KS11) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 226950.KQ
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 226950.KQ
View MoreValuation Measures
Market Cap
720.56B
Enterprise Value
747.34B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
124.01
Price/Book (mrq)
40.37
Enterprise Value/Revenue
131.64
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-22.20%
Return on Equity (ttm)
-118.18%
Revenue (ttm)
5.68B
Net Income Avi to Common (ttm)
-40.66B
Diluted EPS (ttm)
--
Balance Sheet and Cash Flow
Total Cash (mrq)
12.41B
Total Debt/Equity (mrq)
212.16%
Levered Free Cash Flow (ttm)
-22.19B